Archer misses the target
Annexon’s failure in geographic atrophy could clear the way for its rivals.
PTC fails phase 3, and looks to a regulatory filing
Vatiquinone’s pivotal failure in Friedreich’s ataxia prompts a data dredge to come up with a regulatory package. And why not?
